September 2, 2025 · Form 4 insider transaction
Robb Gary Charles bought 251 shares of Corcept Therapeutics Incorporated at $71.38 per share, a transaction worth $17.9K. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 2, 2025.; In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.; Includes 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024, 292 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025 and 997 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 2, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.